Oncolytic vaccinia virus: a theranostic agent for cancer

被引：25

作者：

Chen, Nanhai G. ^{[1
]}

Szalay, Aladar A. ^{[1
,2
,3
,4
]}

机构：

[1] Genelux Corp, San Diego Sci Ctr, San Diego, CA 92109 USA

[2] Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, Inst Biochem, D-97074 Wurzburg, Germany

[3] Univ Wurzburg, Inst Mol Infect Biol, D-97074 Wurzburg, Germany

[4] Univ Calif San Diego, Rebecca & John Moores Comprehens Canc Ctr, Dept Radiat Oncol, La Jolla, CA 92093 USA

来源：

FUTURE VIROLOGY | 2010年 / 5卷 / 06期

关键词：

cancer; chemotherapy; clinical trial; combination therapy; immune response; oncolytic virotherapy; radiotherapy; theranostic; vaccinia virus; CYTOKINE GENE-THERAPY; SINGLE-CHAIN ANTIBODY; RECOMBINANT VACCINIA; THYMIDINE KINASE; GM-CSF; TUMOR-CELLS; HOST-RANGE; NUDE-MICE; IN-VITRO; PHASE-I;

D O I：

10.2217/FVL.10.58

中图分类号：

Q93 [微生物学];

学科分类号：

071005 [微生物学];

摘要：

Vaccinia virus (VACV) is arguably the most successful live biotherapeutic agent because of its critical role in the eradication of smallpox, one of the most deadly diseases in human history. VACV has been exploited as an oncolytic therapeutic agent for cancer since 1922. This virus selectively infects and destroys tumor cells, while sparing normal cells, both in cell cultures and in animal models. A certain degree of therapeutic efficacy also has been demonstrated in patients with different types of cancer. In recent years, several strategies have been successfully developed to further improve its tumor selectivity and antitumor efficacy. Oncolytic VACVs carrying imaging genes represent a new treatment strategy that combines tumor site-specific therapeutics with diagnostics (theranostics).

引用

页码：763 / 784

页数：22

共 199 条

[1]

Angiogenesis: An update and potential drug approaches [J].

Abdelrahim, Maen ;

Konduri, Santhi ;

Basha, Md. Riyaz ;

Philip, Philip A. ;

Baker, Cheryl H. .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2010, 36 (01) :5-18

[2]

Acres B, 1994, Ther Immunol, V1, P17

[3]

Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7 [J].

Akagi, J ;

Hodge, JW ;

McLaughlin, JP ;

Gritz, L ;

Mazzara, G ;

Kufe, D ;

Schlom, J ;

Kantor, JA .

JOURNAL OF IMMUNOTHERAPY, 1997, 20 (01) :38-47

[4]

Oncolytic viruses from the perspective of the immune system [J].

Alemany, Ramon ;

Cascallo, Manel .

FUTURE MICROBIOLOGY, 2009, 4 (05) :527-536

[5]

ALTENBURG LS, 1955, P SOC EXP BIOL MED, V88, P313, DOI 10.3181/00379727-88-21573

[6]

[Anonymous], 1988, Human Monkeypox

[7]

[Anonymous], 1798, INQUIRY CAUSES EFFEC

[8]

CLINICAL-TRIAL OF ATTENUATED VACCINIA VIRUS AS STRAIN IN THE TREATMENT OF ADVANCED ADENOCARCINOMA - REPORT ON 2 CASES [J].

ARAKAWA, S ;

HAMAMI, G ;

UMEZU, K ;

KAMIDONO, S ;

ISHIGAMI, J ;

ARAKAWA, S .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1987, 113 (01) :95-98

[9]

THE EFFECT OF ATTENUATED VACCINIA VIRUS AS STRAIN ON N-METHYL-N'-NITRO-N-NITROSOGUANIDINE-INDUCED GASTRIC-CANCER IN RATS [J].

ARAKAWA, S ;

FUKAI, K .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1983, 105 (02) :117-126

[10]

BASH JA, 1993, ANN NY ACAD SCI, V690, P331

← 1 2 3 4 5 6 7 8 9 10 →